Litcius/Paper detail

Novel Tet(L) Efflux Pump Variants Conferring Resistance to Tigecycline and Eravacycline in Staphylococcus Spp.

Nannan Wang, Dexi Li, Stefan Schwarz, Shangshang Qin, Hong Yao, Xiang-Dang Du

2021Microbiology Spectrum24 citationsDOIOpen Access PDF

Abstract

Tigecycline and eravacycline are both important last-resort broad spectrum antimicrobial agents. The presence of novel Tet(L) efflux pump variants conferring the resistance to tigecycline and eravacycline in Staphylococcus spp. and its potential transmission to S. aureus will compromise the efficacy of tigecycline and eravacycline treatment for S. aureus associated infection in vivo and may lead to clinical treatment failure.

Topics & Concepts

TigecyclineEffluxMicrobiologyStaphylococcus aureusBiologyAntibioticsPlasmidAntibiotic resistanceMultiple drug resistanceDrug resistanceMethicillin-resistant Staphylococcus aureusStaphylococcusStaphylococcal infectionsGeneAntibacterial agentVancomycinGene clusterAntibiotic Resistance in BacteriaAntimicrobial Resistance in StaphylococcusAntibiotics Pharmacokinetics and Efficacy
Novel Tet(L) Efflux Pump Variants Conferring Resistance to Tigecycline and Eravacycline in Staphylococcus Spp. | Litcius